Immunomodulatory enzyme technology company Hansa Biopharma AB (NASDAQ Stockholm: HNSA) revealed on Friday the completion of the sale its entire equity stake in Genovis AB (NASDAQ Stockholm:GENO) for gross proceeds of SEK89m.
Proceeds may be used by Hansa for working capital, to expedite the clinical development programme of imlifidase in transplant rejection and autoimmune diseases, to ramp up preparations for clinical studies with the recently selected lead in the NiceR-programme for development of novel IgG-cleaving enzymes for repeat dosing.
Genovis is reportedly engaged in the development of enzymatic research tools and technologies, applied in e.g. development and quality control of antibody-based drugs.
Earlier in 2011, Hansa Biopharma made a strategic and financial investment in Genovis.
(EUR1=SEK10.4685)
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA